Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

Robert N Reger, Maria Berg, Andreas Lundqvist, PhD, Theresa Donohue, MHS, PA-C, Mattias Carlsten, MD Ph.D, Dawn M Betters, Ph.D, Lisa Cook, RN, BSN, Catalina Ramos, RN, BSN, Sophia Grasmeder, RN, BSN, OCN, Su Su, MD, PhD, David Stroncek, MD, Jeremy Pantin, MD, Keyvan Keyvanfar, BS, Cristian A. Carvallo, MD, Hahn Khuu, MD, Richard Childs, MD

Blood (2011) 118 (21): 1001.

https://doi.org/10.1182/blood.V118.21.1001.1001

Published: 2011

Journal Articles

Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL Cytotoxicity

Aleah Smith, Hahn Khuu, MD, Dawn M Betters, RN, Lisa Cook, RN, BSN, Catalina Ramos, RN, BSN, Sophia Grasmeder, RN, BSN, OCN, Maria Berg, Rebecca Lopez, PhD, Su Su, MD, PhD, Vicki Fellowes, MT, David Stroncek, MD, Jeremy Pantin, MD, Sumi Vasu, MD, Theresa Donohue, MHS, PA-C, Keyvan Keyvanfar, BS, Richard Childs, MD

Blood (2010) 116 (21): 4296.

https://doi.org/10.1182/blood.V116.21.4296.4296

Published: 2010

Journal Articles

Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT).

Elena Cherkasova, Elizabeth Malinzak, Sheila Rao, Vera N. Senchenko, Anna V. Kudryavtseva, Lev L. Kiselev, Yoshiyuki Takahashi, MD, PhD, Nanae Harashima, W. Marston Linehan, M.D, Ramaprasad Srinivasan, MD, PhD, Michael I. Lerman, Richard W. Childs, MD

Blood (2009) 114 (22): 467.

https://doi.org/10.1182/blood.V114.22.467.467

Published: 2009

Journal Articles

Causes of Death for Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Imatinib.

Andrea Renata Dean, MD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Mary Beth Rios, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Jianqin Shan, Ph.D, Jorge Cortes, MD

Blood (2009) 114 (22): 4279.

https://doi.org/10.1182/blood.V114.22.4279.4279

Published: 2009

Journal Articles

Organization and Physiologically Mediated Differential Release of Angiogenic Regulatory Proteins From Distinct Platelet Alpha Granules.

Elisabeth Battinelli, MD, PhD, Joseph Italiano, Jr, PhD

Blood (2009) 114 (22): 3045.

https://doi.org/10.1182/blood.V114.22.3045.3045

Published: 2009

Journal Articles

Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma

Lauren C. Harshman, M.D., Calvin J. Kuo, M.D., Ph.D., Bryan Y. Wong, M.D., Ph.D., Nicholas J. Vogelzang, M.D., Sandy Srinivas, M.D.

Blood (2008) 112 (11): 3453.

https://doi.org/10.1182/blood.V112.11.3453.3453

Published: 2008

Journal Articles

NK Cell Anti-Tumor Immune Responses Are Impaired by Sorafenib but Not by Sunitinib

Matthias Krusch, MD, Manuela Schlicke, Julia Salih, Tina Baessler, Lothar Kanz, MD, Helmut Salih, MD

Blood (2008) 112 (11): 2632.

https://doi.org/10.1182/blood.V112.11.2632.2632

Published: 2008

Journal Articles

Impact of KIR and HLA Genotypes on Outcome in Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Using HLA Matched Related Donors.

Ramaprasad Srinivasan, MD, PhD, Mary Carrington, Ph.D., Dante Suffredini, M.S., Aleah Smith, Maureen Martin, Ph.D, Maria Berg, M.S., A. John Barrett, M.D., Shivani Srivastava, M.D, Andreas Lundqvist, Ph.D., Hisayuki Yokoyoma, M.D., Bipin N. Savani, M.D., Richard W. Childs, M.D.

Blood (2006) 108 (11): 323.

https://doi.org/10.1182/blood.V108.11.323.323

Published: 2006

Journal Articles

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

Adi Gidron, MD, John Eklund, MD, Brenda Martone, RN, MSN, Alfred W. Rademaker, PhD, Charles Goolsby, PhD, Laura Marszalek, Timothy M. Kuzel, MD

Blood (2006) 108 (11): 1729.

https://doi.org/10.1182/blood.V108.11.1729.1729

Published: 2006

Journal Articles

In Vitro and In Vivo Sensitization of Malignant Cells to Autologous Natural Killer Cell Cytotoxicity Following Exposure to Bortezomib.

Andreas Lundqvist, PhD, Kristy Greeneltch, PhD, Maria Berg, MS, Shivani Srivastava, MD, Nanae Harashima, PhD, Hisayuki Yokoyama, PhD, Aleah Smith, MS, Scott Abrams, PhD, Richard Childs, MD

Blood (2006) 108 (11): 925.

https://doi.org/10.1182/blood.V108.11.925.925

Published: 2006

Journal Articles

Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation in Renal Cell Carcinoma: The EIO Experience.

Rocco Pastano, MD, Daniele Laszlo, MD, Giovanna Andreola, MD, Federica Gigli, MD, Cristina Rabascio, Valentina Raia, Manuela Cazzanti, Fedro Peccatori, MD, Giovanni Martinelli, MD

Blood (2005) 106 (11): 5424.

https://doi.org/10.1182/blood.V106.11.5424.5424

Published: 2005

Journal Articles

Tumor Control Achieved Despite Loss of Chimaerism in Renal Cell Carcinoma (RCC) Following Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Case Report.

Giovanna Andreola, MD, Federica Gigli, MD, Cristina Rabascio, Manuela Cazzanti, Fedro Peccatori, MD, Saverio Cinieri, MD, Rocco Pastano, MD, Giovanni Martinelli, MD

Blood (2005) 106 (11): 5401.

https://doi.org/10.1182/blood.V106.11.5401.5401

Published: 2005

Journal Articles

A Polymorphic Oncofetal Antigen Recognized by CD8 + CTL from Two Patients Experiencing Regression of Metastatic Renal Cell Carcinoma after Allogeneic HCT.

Edus H. Warren, MD, PhD, Jeffrey K. Mito, Scott S. Tykodi, MD, PhD, John A. Thompson, MD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Stanley R. Riddell, MD, Benoît Van den Eynde, MD

Blood (2005) 106 (11): 3097.

https://doi.org/10.1182/blood.V106.11.3097.3097

Published: 2005

Journal Articles

Intradermal RNA-Vaccination of Patients with Metastatic Renal Cell Carcinoma.

Jan Wierecky, PhD, Martin R. Müller, MD, PhD, Maik Häntschel, Marius S. Horger, Steve Pascolo, Wolfram Brugger, Lothar Kanz, MD, Peter Brossart, MD

Blood (2005) 106 (11): 3881.

https://doi.org/10.1182/blood.V106.11.3881.3881

Published: 2005

Journal Articles

Entry Bias: Order of Patient Entry Influences Outcome in Trials of Allogeneic Transplant for Renal Cell Carcinoma.

Andrew S. Artz, MD, MS, Masha Kocherginsky, Ph.D, Koen Van Besien, MD

Blood (2004) 104 (11): 269.

https://doi.org/10.1182/blood.V104.11.269.269

Published: 2004

Journal Articles

Potent Graft-Versus-Renal Cell Carcinoma (RCC) Effects in a Murine Minor Histocompatibility Antigen (mHa)-Mismatched Allogeneic Transplant Model.

Andreas Lundqvist, PhD, Ramaprasad Srinivasan, MD, PhD, Dante Suffredini, BS, Yoshiyuki Takahashi, MD, PhD, Jason Wynberg, MD, Takehito Igarashi, MD, PhD, Amy Reese, MD, Warren Shlomchik, MD, Richard Childs, MD

Blood (2004) 104 (11): 4982.

https://doi.org/10.1182/blood.V104.11.4982.4982

Published: 2004

Journal Articles

Nonmyeloablative Allogeneic Stem Cell Transplantation: Hacettepe University Institute of Oncology Experience.

Yener Koc, MD, Evren Ozdemir, MD, Basak Oyan, MD, Emin Kansu, MD

Blood (2004) 104 (11): 5155.

https://doi.org/10.1182/blood.V104.11.5155.5155

Published: 2004

Journal Articles

Cd8+ T-Cells Specifically Cytotoxic to Renal Cell Carcinoma (RCC) Cells Can Be Isolated from Patients with Regressing Metastatic Kidney Cancer after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (NMHCT).

Yoshiyuki Takahashi, MD, PhD, Othon Mena, MD, Ramaprasad Srinivasan, MD, PhD, Takehito Igarashi, MD, PhD, Andreas Lundqvist, PhD, Dante Suffredini, J. Philip McCoy, Jr, PhD, Ken-ichi Hanada, MD, PhD, Marston Linehan, MD, Richard Childs, MD

Blood (2004) 104 (11): 4984.

https://doi.org/10.1182/blood.V104.11.4984.4984

Published: 2004

Journal Articles

Phase I/II Trial of Dendritic Cells Pulsed with Telomerase.

Angela Marten, Ph.D., Elisabeth Sievers, Ph.D., Peter Albers, MD, Stefan Muller, MD, Christian Franchy, MD, Alexander von Rucker, MD, Holger Strunk, MD, Hans H. Schild, MD, Tilman Sauerbruch, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2004) 104 (11): 1353.

https://doi.org/10.1182/blood.V104.11.1353.1353

Published: 2004

Journal Articles

CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.

Brian I. Rini, MD, Susan Halabi, PhD, Robert Barrier, PhD, Kim A. Margolin, MD, David Avigan, MD, Theodore Logan, MD, Philip L. McCarthy, MD, Eric S. Small, MD, Charles A. Linker, MD

Blood (2004) 104 (11): 810.

https://doi.org/10.1182/blood.V104.11.810.810

Published: 2004

NARROW

A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity

Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL Cytotoxicity

Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT).

Causes of Death for Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Imatinib.

Organization and Physiologically Mediated Differential Release of Angiogenic Regulatory Proteins From Distinct Platelet Alpha Granules.

Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma

NK Cell Anti-Tumor Immune Responses Are Impaired by Sorafenib but Not by Sunitinib

Impact of KIR and HLA Genotypes on Outcome in Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Using HLA Matched Related Donors.

Concurrent Treatment with Denileukin Diftitox (DD) To Deplete T-Regulatory Cells Enhances Rebound Lymphocytosis and Eosinophilia in Patients Treated with High-Dose IL-2 (HDIL-2) for Metastatic Renal Cell Cancer (MRCC).

In Vitro and In Vivo Sensitization of Malignant Cells to Autologous Natural Killer Cell Cytotoxicity Following Exposure to Bortezomib.

Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation in Renal Cell Carcinoma: The EIO Experience.

Tumor Control Achieved Despite Loss of Chimaerism in Renal Cell Carcinoma (RCC) Following Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): A Case Report.

A Polymorphic Oncofetal Antigen Recognized by CD8 + CTL from Two Patients Experiencing Regression of Metastatic Renal Cell Carcinoma after Allogeneic HCT.

Intradermal RNA-Vaccination of Patients with Metastatic Renal Cell Carcinoma.

Entry Bias: Order of Patient Entry Influences Outcome in Trials of Allogeneic Transplant for Renal Cell Carcinoma.

Potent Graft-Versus-Renal Cell Carcinoma (RCC) Effects in a Murine Minor Histocompatibility Antigen (mHa)-Mismatched Allogeneic Transplant Model.

Nonmyeloablative Allogeneic Stem Cell Transplantation: Hacettepe University Institute of Oncology Experience.

Cd8+ T-Cells Specifically Cytotoxic to Renal Cell Carcinoma (RCC) Cells Can Be Isolated from Patients with Regressing Metastatic Kidney Cancer after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (NMHCT).

Phase I/II Trial of Dendritic Cells Pulsed with Telomerase.

CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only